AR072185A1 - Agonistas de receptores s1p1 y uso de los mismos - Google Patents

Agonistas de receptores s1p1 y uso de los mismos

Info

Publication number
AR072185A1
AR072185A1 ARP090102221A ARP090102221A AR072185A1 AR 072185 A1 AR072185 A1 AR 072185A1 AR P090102221 A ARP090102221 A AR P090102221A AR P090102221 A ARP090102221 A AR P090102221A AR 072185 A1 AR072185 A1 AR 072185A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkyl
substituted
cr10r10
formula
Prior art date
Application number
ARP090102221A
Other languages
English (en)
Spanish (es)
Inventor
Kelvin K C Sham
Victor J Cee
Brian Alan Lanman
Anthony B Reed
Susana C Neira
Michael J Frohn
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR072185A1 publication Critical patent/AR072185A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
ARP090102221A 2008-06-20 2009-06-18 Agonistas de receptores s1p1 y uso de los mismos AR072185A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7447608P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
AR072185A1 true AR072185A1 (es) 2010-08-11

Family

ID=41434357

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102221A AR072185A1 (es) 2008-06-20 2009-06-18 Agonistas de receptores s1p1 y uso de los mismos

Country Status (10)

Country Link
US (2) US7842685B2 (https=)
EP (1) EP2306994B1 (https=)
JP (1) JP5571073B2 (https=)
AR (1) AR072185A1 (https=)
AU (1) AU2009260726B2 (https=)
CA (1) CA2728046A1 (https=)
ES (1) ES2433579T3 (https=)
MX (1) MX2010013555A (https=)
TW (1) TW201000099A (https=)
WO (2) WO2009154780A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079981A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de acido carboxilico que comprenden un anillo de oxoazolopirimidina 2,5,7- sustituido
UY33178A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de ácido carboxílico heteroxíclicos que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido
AR079980A1 (es) 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
CN102791717B (zh) 2010-01-14 2016-03-30 赛诺菲 具有2,5-取代的噁唑并嘧啶环的羧酸衍生物
CN102834400B (zh) * 2010-01-14 2015-06-10 赛诺菲 2,5-取代的*唑并嘧啶衍生物
DK2523960T3 (da) * 2010-01-14 2014-01-20 Sanofi Sa Heterocykliske carboxylsyrederivater med en 2,5-substitueret oxazolopyrimidinring
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
MX2013003019A (es) 2010-09-15 2013-05-28 Hoffmann La Roche Compuestos de azabenzotiazol, composiciones y metodos de uso.
WO2012130633A1 (en) * 2011-03-25 2012-10-04 Boehringer Ingelheim International Gmbh Pyrazole compounds as crth2 antagonists
US9321787B2 (en) 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
US8907093B2 (en) 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
US8580816B2 (en) 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
WO2013158422A1 (en) 2012-04-17 2013-10-24 E. I. Du Pont De Nemours And Company Heterocyclic compounds for controlling invertebrate pests
CN104380596B (zh) * 2012-07-20 2018-01-02 三菱电机株式会社 保持框架和太阳能电池模块
JP2016509036A (ja) 2013-02-20 2016-03-24 バイエル・ファルマ・アクティエンゲゼルシャフト Ｍｋｎｋ１阻害剤としての置換イミダゾ［１，２−ｂ］ピリダジン
NZ716822A (en) 2013-08-21 2017-10-27 Alios Biopharma Inc Antiviral compounds
WO2016182850A1 (en) 2015-05-08 2016-11-17 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
CN110256466A (zh) * 2019-07-31 2019-09-20 昆山迪安医学检验实验室有限公司 一种噻唑[5,4-b]-吡啶基生物活性化合物的制备方法及其抗肿瘤活性的检测
EP4061352A4 (en) 2019-11-19 2024-02-28 Trevena, Inc. COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS
CN115611793A (zh) * 2021-07-14 2023-01-17 山东新华制药股份有限公司 硫代酰胺类化合物的合成方法
CN116410213A (zh) * 2023-02-21 2023-07-11 武汉大学 一种合成3-碳基-1-硼基环类化合物的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
AU2001292350A1 (en) 2000-10-05 2002-04-15 Takeda Chemical Industries Ltd. Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells
US6951848B2 (en) 2001-03-12 2005-10-04 Millennium Pharmaceuticals, Inc., Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
AU2002349477A1 (en) 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
CA2523677A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
BRPI0410439A (pt) * 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
EP1799659A1 (en) 2004-10-13 2007-06-27 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
US7919519B2 (en) * 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
EP1965807A4 (en) * 2005-11-23 2010-10-27 Epix Delaware Inc S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE
US20090182003A1 (en) 2006-01-13 2009-07-16 President And Fellows Of Harvard College Methods and Compositions for Treatment Cell Proliferative Disorders
JP2009526761A (ja) 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
JP4897834B2 (ja) 2006-02-08 2012-03-14 コダック グラフィック コミュニケーションズ ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンゾキサゾール誘導体およびその類似体を増感剤として含む紫外線感受性平版印刷版前駆体
JP2009530389A (ja) * 2006-03-21 2009-08-27 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物及びその使用
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US20100055071A1 (en) 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
CA2671315A1 (en) 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia by inhibiting dgat1 enzyme with a dgat1 inhibitor
MX2009010060A (es) 2007-03-21 2010-01-20 Epix Pharm Inc Compuestos moduladores del receptor de esfingosin-1-fosfato y uso de los mismos.
JP2008308448A (ja) 2007-06-15 2008-12-25 Sankyo Agro Kk （３−硫黄原子置換フェニル）へテロアリール誘導体
ES2360929T3 (es) * 2007-09-20 2011-06-10 Amgen Inc. Derivados del ácido 1-(4-(4-bencilbenzamido)-bencil)azetidin-3-carboxílico y compuestos relacionados como moduladores del receptor s1p para el tratamiento de trastornos inmunitarios.

Also Published As

Publication number Publication date
ES2433579T3 (es) 2013-12-11
EP2306994B1 (en) 2013-08-14
EP2306994A1 (en) 2011-04-13
TW201000099A (en) 2010-01-01
AU2009260726A1 (en) 2009-12-23
MX2010013555A (es) 2011-01-14
WO2009154780A1 (en) 2009-12-23
JP5571073B2 (ja) 2014-08-13
WO2009154775A1 (en) 2009-12-23
AU2009260726B2 (en) 2014-03-27
US20100029611A1 (en) 2010-02-04
JP2011524906A (ja) 2011-09-08
CA2728046A1 (en) 2009-12-23
US20120129828A1 (en) 2012-05-24
US7842685B2 (en) 2010-11-30
EP2306994A4 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
AR072185A1 (es) Agonistas de receptores s1p1 y uso de los mismos
MX2020000261A (es) Nuevos compuestos.
SG195106A1 (en) Trpv4 antagonists
AR124662A2 (es) Formulaciones inmunosupresoras
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
AR057702A1 (es) Inhibidores macrociclicos del virus de la hepatitis c, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para la profilaxis o el tratamiento de infecciones por flavivirus
AR067475A1 (es) Antagonistas no basico s del receptor de la hormona concentradora de melanina 1
PE20170438A1 (es) Inhibidores espirociclicos de catepsina c
AR055212A1 (es) Compuestos heterociclicos como bloqueantes del canal ionico p2x7
GEP201606526B (en) 5-ht3 receptor antagonists
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
PH12012501851A1 (en) Tetrahydrobenzothiophene compound
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
AR054485A1 (es) ARIL-ALQUILAMINAS Y HETEROARIL-ALQUILAMINAS COMO INHIBIDORES DE PROTEINA QUINASA A Y B, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ORIGINADAS EN EL CRECIMIENTO ANORMAL DE LA
AR061015A1 (es) Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto
MX2018014944A (es) Tratamiento para la enfermedad de parkinson.
AR074817A1 (es) Dihidropiridona-amidas como moduladores de p2x7
AR118983A1 (es) Antagonistas cíclicos del receptor b2 de bradiquinina
UY37981A (es) Novedosos antagonistas del receptor b2 de bradiquinina
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
MX2012009224A (es) Compuestos en calidad de antagonistas de bradiquinina-b1.
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
BR112013003752A2 (pt) compostos de tetra-hidrofuranila dissubstituídos como antagonistas do receptor de bradiquinina b1

Legal Events

Date Code Title Description
FB Suspension of granting procedure